CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)
Grace S. Ahn, Kihwan Hwang, Tae Min Kim, Chul Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo, Yong-Kil Hong, Eun-Young Kim, Dong-Eun Lee, Jungnam Joo, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Seok-Gu Kang, Jeong Hoon Kim, Chae-Yong Kim
Cancer Research and Treatment. 2022;54(2):396-405.   Published online 2021 July 6    DOI: https://doi.org/10.4143/crt.2021.393

Excel Download

Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)
Cancer Research and Treatment. 2022;54(2):396-405   Crossref logo
Link1 Link2 Link3

ACTR-50. EFFECT OF CONCURRENT AND ADJUVANT TEMOZOLOMIDE ON SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED GRADE III GLIOMAS WITHOUT 1p/19q CO-DELETION: A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY (INTERIM RESULTS FROM THE KNOG-1101 STUDY)
Neuro-Oncology. 2018;20(suppl_6):vi23-vi23   Crossref logo
Link1

Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study)
Cancer Research and Treatment. 2020;52(2):505-515   Crossref logo
Link1 Link2 Link3

ACTR-14. A PROSPECTIVE RANDOMIZED STUDY OF CONCURRENT CHEMORADIOTHERAPY WITH TEMOZOLOMIDE VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH IDH WILD-TYPE/TERT PROMOTER MUTATION GRADE II/III GLIOMAS
Neuro-Oncology. 2019;21(Supplement_6):vi15-vi15   Crossref logo
Link1 Link2

SYST-10 CSNO2012001 STUDY: A PHASE III TRIAL ON ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY WITH OR WITHOUT INTERFERON-ALPHA IN NEWLY DIAGNOSED HIGH-GRADE GLIOMAS
Neuro-Oncology Advances. 2022;4(Supplement_1):i23-i23   Crossref logo
Link1 Link2

CTNI-33. CSNO2012001 STUDY: A PHASE III TRIAL ON ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY WITH OR WITHOUT INTERFERON-ALPHA IN NEWLY DIAGNOSED HIGH-GRADE GLIOMAS
Neuro-Oncology. 2022;24(Supplement_7):vii78-vii78   Crossref logo
Link1 Link2

Health-related quality of life aspects in patients with low-grade glioma
Low-Grade Gliomas. 2010;213-235   Crossref logo
Link1

Health related quality of life improvement in chronic non-specific neck pain: secondary analysis from a single blinded, randomized clinical trial
Health and Quality of Life Outcomes. 2018;16(1):   Crossref logo
Link1 Link2 Link3

Importance of evaluating health-related quality of life issues in survivors of WHO grade II or III gliomas
Neuro-Oncology Practice. 2022;9(1):1-2   Crossref logo
Link1 Link2

Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery:Study protocol for a randomized controlled clinical trial
. 2019;   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.